|Drug Name:||Lithium Carbonate Extended Release|
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.] Protect from moisture.Dispense in tight, child-resistant container (USP).10002523/02Revised November 2005© RLI, 2005
Lithium is indicated in the treatment of manic episodes of manic-depressive illness.Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.
Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation, dehydration, sodium depletion, and to patients receiving diuretics, or angiotensin converting enzyme (ACE) inhibitors, since the risk of lithium toxicity is very high in such patients.
If the psychiatric indication is life threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals.
In such instances, hospitalization is a necessity.Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia.
Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity.
This condition is usually reversible when lithium is discontinued.Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy.
Morphologic changes have also been seen in manic-depressive patients never exposed to lithium.
The relationship between renal function and morphologic changes and their association with lithium therapy have not been established.Kidney function should be assessed prior to and during lithium therapy.
Routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance).
During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for re-evaluation of treatment.An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus a neuroleptic, most notably haloperidol.
In some instances, the syndrome was followed by irreversible brain damage.
Because of possible causal relationship between these events and the concomitant administration of lithium and neuroleptic drugs, patients receiving such combined therapy or patients with organic brain syndrome or other CNS impairment should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear.
This encephalopathic syndrome may be similar to or the same as Neuroleptic Malignant Syndrome (NMS).Lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to the therapeutic concentrations (see DOSAGE AND ADMINISTRATION).Outpatients and their families should be warned that the patient must discontinue lithium therapy and contact his physician if such clinical signs of lithium toxicity as diarrhea, vomiting, tremor, mild ataxia, drowsiness, or muscular weakness occur.Lithium may prolong the effects of neuromuscular blocking agents.Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.